Develop a new antibody to enhance cancer treatment
DEVELOP A NONCOMPETITIVE MONOCLONAL ANTI-CD25
['FUNDING_OTHER'] · LEIDOS BIOMEDICAL RESEARCH, INC. · NIH-10291511
This study is testing a new treatment that uses a special antibody to help your immune system better fight cancer by targeting specific cells that usually keep it from working, and it combines this with light therapy to make the treatment even more effective.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LEIDOS BIOMEDICAL RESEARCH, INC. (nih funded) |
| Locations | 1 site (FREDERICK, UNITED STATES) |
| Trial ID | NIH-10291511 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a monoclonal antibody that targets CD25, a marker found on regulatory T-cells that suppress the immune response in tumors. By combining this antibody with a photoimmunotherapy approach, where light is used to activate a special photoabsorber linked to the antibody, the goal is to improve the effectiveness of cancer treatments. The therapy aims to not only kill the targeted tumors but also stimulate a broader immune response that can prevent tumor reimplantation. Patients may benefit from this innovative approach as it seeks to enhance the body’s ability to fight cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that express CD25 and are seeking advanced treatment options.
Not a fit: Patients with tumors that do not express CD25 or those who are not eligible for photoimmunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the immune system to combat tumors.
How similar studies have performed: Other research has shown promising results with similar approaches, particularly in the use of photoimmunotherapy combined with immune-targeting strategies.
Where this research is happening
FREDERICK, UNITED STATES
- LEIDOS BIOMEDICAL RESEARCH, INC. — FREDERICK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DMITROVSKY, ETHAN — LEIDOS BIOMEDICAL RESEARCH, INC.
- Study coordinator: DMITROVSKY, ETHAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.